List view / Grid view
Crohn’s disease is a type of inflammatory bowel disease that may affect any part of the gastrointestinal tract from mouth to anus. Signs and symptoms often include abdominal pain, diarrhea (which may be bloody if inflammation is severe), fever, and weight loss.
Other complications may occur outside the gastrointestinal tract and include anemia, skin rashes, arthritis, inflammation of the eye, and feeling tired. The skin rashes may be due to infections as well as pyoderma gangrenosum or erythema nodosum. Bowel obstruction also commonly occurs and those with the disease are at greater risk of bowel cancer.
Crohn’s disease is caused by a combination of environmental, immune and bacterial factors in genetically susceptible individuals. It results in a chronic inflammatory disorder, in which the body’s immune system attacks the gastrointestinal tract possibly directed at microbial antigens. While Crohn’s is an immune related disease, it does not appear to be an autoimmune disease (in that the immune system is not being triggered by the body itself). The exact underlying immune problem is not clear; however, it may be an immunodeficiency state. About half of the overall risk is related to genetics with more than 70 genes found to be involved.
23 February 2015 | By TiGenix NV
TiGenix NV has announced that Dr Julian Panés endorsed the design of the Company's Phase III trial of Cx601 for the treatment of complex perianal fistulas in patients with Crohn's disease during his presentation last week at the 10th Annual Congress of the European Crohn's and Colitis Organisation (ECCO)...
Lonza, a global leader in biological and cell therapy manufacturing and TiGenix, an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from allogeneic expanded adipose-derived stem cells (eASCs) in inflammatory and autoimmune diseases, announced today an agreement for the supply of TiGenix's eASC product, Cx601.
12 November 2014 | By TiGenix NV
TiGenix NV announced that it has completed the patient recruitment for its Phase III trial of Cx601 in Europe for the treatment of complex perianal fistulas in Crohn's patients...
26 September 2014 | By AbbVie
AbbVie announced that the U.S. Food and Drug Administration has approved HUMIRA® (adalimumab) for reducing signs and symptoms, and achieving and maintaining clinical remission, in pediatric Crohn's disease patients 6 years of age and older when certain other treatments have not worked well enough...
11 June 2014 | By AbbVie
AbbVie announced results from its multi-country ALIGN study, which shows that across six chronic immune-mediated inflammatory diseases...
19 December 2013 | By Sandoz
Sandoz advances leading biosimilars pipeline by strengthening Immunology portfolio...
23 August 2013 | By GlaxoSmithKline
The first of four Phase III studies, the SHIELD-1 study, investigating vercirnon in adult patients with moderately-to-severely active Crohn’s disease did not achieve the primary endpoint...
27 November 2012 | By Abbott
Abbott announced that the European Commission has approved HUMIRA®...
22 October 2012 | By Abbott
Results from an analysis of three-year long-term data...
22 October 2012 | By Teva Pharmaceutical Industries Ltd
TEVA and Active Biotech announced the presentation of Phase IIa clinical data...
19 October 2012 | By Abbott
The CHMP has adopted a positive opinion for HUMIRA®...
30 August 2012 | By Abbott
Approval extends HUMIRA indication to include moderately active Crohn's Disease...
29 May 2012 | By Abbott
Latest investigational research findings on HUMIRA®...
30 March 2011 | By UK National Stem Cell Network (UKNSCN)
Professor Miguel Forte will describe research into a new cell therapy at the UK National Stem Cell Network annual science meeting...
